American College of Radiology (ACR) · 2022

Palpable Breast Mass — Age-Based Imaging & Biopsy Pathway

Source: ACR Appropriateness Criteria: Palpable Breast Masses, 2022 Update, Journal of the American College of Radiology

Guideline: Strong Guideline: Conditional Guideline: Not recommended ClinicoQ pathway suggestion (not from the cited guideline)

Diagnosis

Diagnostic criteria A new palpable breast mass requires a thorough clinical breast exam plus imaging in almost all cases, since exam findings alone cannot reliably distinguish benign from malignant masses. Imaging choice is age-stratified (see workup). If imaging is BI-RADS 4/5 (suspicious/highly suggestive of malignancy), image-guided core biopsy is indicated; if benign/probably benign (BI-RADS 1-3), further imaging is generally not needed unless the clinical exam remains concerning.

⚠ Alarm features (investigate before diagnosing)

Skin changes (dimpling, peau d'orange, ulceration)
Nipple retraction or bloody nipple discharge
Axillary lymphadenopathy
Rapidly enlarging or fixed, hard, irregular mass on exam — clinical suspicion can warrant biopsy even with reassuring imaging

Initial workup

Test	When to order
Ultrasound (targeted breast US)	First-line/primary imaging for women under 30; combined with mammography/tomosynthesis for ages 30-39; used as an adjunct for women 40+ if mammogram is negative but suspicion remains, or immediately if mammography is suspicious.
Diagnostic mammography / tomosynthesis	Initial imaging of choice for women 40 and older; used alongside ultrasound for ages 30-39.
Image-guided core biopsy	When imaging shows a suspicious finding (BI-RADS 4/5); preferred over FNA for sensitivity/specificity, though some practices use FNA as an initial step.

Decision Points

❓ What is the patient's age?

Under 30 years → Ultrasound first (age <30)

30–39 years → Ultrasound + mammography/tomosynthesis (age 30-39)

40 years or older → Diagnostic mammography/tomosynthesis first (age ≥40)

❓ What is the BI-RADS assessment on imaging?

BI-RADS 1–3 (negative/benign/probably benign) → No further imaging; clinical follow-up

BI-RADS 4–5 (suspicious/highly suggestive of malignancy) → Image-guided core biopsy

Treatment

Ultrasound first (age <30)

1 Targeted breast ultrasound Strong (Guideline recommendation)

Dose: — imaging study
Duration: Initial workup step
Evidence level: Moderate
Avoid if: —
If no response ClinicoQ pathway: If suspicious findings, proceed to biopsy; note there is no evidence to support image-guided FNA as an initial workup step in women under 30 with a probably benign ultrasound

Ultrasound + mammography/tomosynthesis (age 30-39)

1 Ultrasound and diagnostic mammography/tomosynthesis Strong (Guideline recommendation) — both usually appropriate in this age group

Dose: — imaging studies
Duration: Initial workup step
Evidence level: Moderate
Avoid if: —
If no response ClinicoQ pathway: Proceed to biopsy if suspicious findings on either modality

Diagnostic mammography/tomosynthesis first (age ≥40)

1 Diagnostic mammography or tomosynthesis Strong (Guideline recommendation)

Dose: — imaging study
Duration: Initial workup step
Evidence level: Moderate
Avoid if: —
If no response ClinicoQ pathway: Add ultrasound if the patient had a negative mammogram within the past 6 months, or immediately if mammography findings are suspicious

Image-guided core biopsy

1 Ultrasound-guided (or mammography-guided) core needle biopsy Strong (Guideline recommendation) — core biopsy generally preferred over FNA for accuracy

Dose: — procedure
Duration: After suspicious imaging finding, unless contraindicated
Evidence level: Moderate
Avoid if: Comorbidities that would contraindicate biopsy (rare)
If no response ClinicoQ pathway: Refer to breast surgery/oncology based on histopathology results

No further imaging; clinical follow-up

1 Routine clinical follow-up; no further imaging needed Strong (Guideline recommendation)

Dose: —
Duration: Per routine screening schedule, unless the clinical exam remains concerning
Evidence level: Moderate
Avoid if: Physical exam findings remain concerning despite benign imaging — discuss biopsy based on clinical suspicion
If no response: —

✕ Treatments the guideline advises against

Breast MRI, PEM, or molecular breast imaging as routine initial evaluation of a palpable mass: Guideline states there is little role for these advanced technologies in the initial evaluation of a palpable mass.

Image-guided core biopsy as the very first workup step in women under 30: No evidence supports this as an initial step; imaging (ultrasound) should come first.

⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.